HUTCHMED (China) Limited American Depositary Shares (HCM) Stock Price

HCMStock

$12.38−33.04%52W

Market Cap$2.15B

P/E4.74x

PEG Ratio—

Div yield—

Beta1.08

HCM Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)-26.75%

Price vs S&P 500 (4W)8.08%

VGM Score50.99

P/E Ratio (Annual)4.74x

P/CF (Annual)4930.73x

Book Value / Share (Quarterly)$1.42

Revenue Growth (3Y)8.76%

Cash Flow / Share (Quarterly)$-0.10

Price vs S&P 500 (YTD)-15.40%

Gross Margin (TTM)38.68%

Net Profit Margin (TTM)83.30%

EPS (TTM)$0.52

10-Day Avg Trading Volume5.97M

EPS Excl Extra (TTM)$0.52

Revenue Growth (5Y)19.20%

EPS (Annual)$0.52

ROI (Annual)34.20%

Gross Margin (Annual)38.68%

Net Profit Margin (5Y Avg)-7.59%

Cash / Share (Quarterly)$1.57

P/E Basic Excl Extra (TTM)4.74x

Revenue Growth QoQ (YoY)-16.54%

P/E Normalized (Annual)4.74x

ROA (Last FY)26.06%

Revenue Growth TTM (YoY)-12.96%

EBITD / Share (TTM)$-0.03

ROE (5Y Avg)-20.94%

Operating Margin (TTM)-7.14%

Cash Flow / Share (Annual)$-0.10

P/B Ratio1.75x

P/B Ratio (Quarterly)1.84x

Net Income / Employee (Annual)$254,400

Net Interest Coverage (TTM)13.00x

ROA (TTM)25.89%

EPS Growth QoQ (YoY)-83.94%

EPS Incl Extra (Annual)$0.52

Current Ratio (Annual)4.96x

Quick Ratio (Quarterly)4.81x

3-Month Avg Trading Volume4.27M

52-Week Price Return-33.04%

P/E Incl Extra (TTM)4.74x

Revenue / Employee (TTM)$305,400

P/S Ratio (Annual)3.95x

Asset Turnover (Annual)0.31x

52-Week High$28.80

Operating Margin (5Y Avg)-33.42%

EPS Excl Extra (Annual)$0.52

CapEx CAGR (5Y)4.28%

26-Week Price Return-14.82%

Quick Ratio (Annual)4.81x

13-Week Price Return11.47%

Total Debt / Equity (Annual)0.08x

Current Ratio (Quarterly)4.96x

Enterprise Value$2.19B

Revenue / Share Growth (5Y)13.98%

Asset Turnover (TTM)0.31x

Revenue / Employee (Annual)$305,400

Inventory Turnover (Annual)6.73x

Pretax Margin (Annual)95.05%

Cash / Share (Annual)$1.57

3-Month Return Std Dev37.79%

Gross Margin (5Y Avg)38.39%

Net Income / Employee (TTM)$254,400

ROE (Last FY)36.91%

Net Interest Coverage (Annual)3.54x

EPS Basic Excl Extra (Annual)$0.52

P/FCF (TTM)644.96x

Receivables Turnover (TTM)3.86x

Total Debt / Equity (Quarterly)0.08x

EPS Incl Extra (TTM)$0.52

Receivables Turnover (Annual)4.73x

ROI (TTM)34.38%

P/S Ratio (TTM)3.95x

Pretax Margin (5Y Avg)-2.66%

Revenue / Share (Annual)$0.63

Forward P/E53.77x

Price vs S&P 500 (52W)-55.25%

P/E Ratio (TTM)4.74x

EPS Growth TTM (YoY)1109.24%

Year-to-Date Return-3.83%

5-Day Price Return2.85%

EPS Normalized (Annual)$0.52

ROA (5Y Avg)-12.66%

Net Profit Margin (Annual)83.30%

Month-to-Date Return11.97%

EBITD / Share (Annual)$-0.03

Operating Margin (Annual)-7.16%

LT Debt / Equity (Annual)0.06x

ROI (5Y Avg)-19.80%

P/E Excl Extra (TTM)4.74x

LT Debt / Equity (Quarterly)0.06x

EPS Basic Excl Extra (TTM)$0.52

P/B Ratio (Annual)1.84x

Inventory Turnover (TTM)7.09x

Pretax Margin (TTM)95.05%

Book Value / Share (Annual)$1.42

Price vs S&P 500 (13W)9.51%

Beta1.08x

P/FCF (Annual)11.60x

Revenue / Share (TTM)$0.63

ROE (TTM)37.04%

52-Week Low$15.57

vGradeC

gGradeC

mGradeC

vgmGradeC

HCM Analyst Recommendations

May 2026

Jun 2026

Jul 2026

Aug 2026

4.22

4.27

4.23

Industry Peers — Pharmaceuticals(570)

Symbol	Value Score	Growth Score	Momentum Score	Price
HCMHUTCHMED (China) Limited American Depositary Shares	C	C	C	$12.38
LLYEli Lilly & Co.	D	B	C	$1174.61
JNJJohnson & Johnson	D	C	B	$268.04
ABBVABBVIE INC.	D	C	B	$255.48
MRKMerck & Co., Inc.	D	C	B	$148.35
NVSNovartis AG	C	C	C	$153.81
AZNAstraZeneca PLC	C	B	C	$162.70
NVONovo-Nordisk A/S	B	C	C	$45.61
ABTAbbott Laboratories	C	C	C	$112.47
PFEPfizer Inc.	C	D	B	$27.96
VRTXVertex Pharmaceuticals Inc	D	C	B	$541.69
BMYBristol-Myers Squibb Co.	B	B	B	$66.58
SNYSanofi American Depositary Shares (Each representing one-half of one ordinary share)	B	C	C	$44.82
GSKGSK plc American Depositary Shares (Each representing two Ordinary Shares)	B	C	C	$50.82
REGNRegeneron Pharmaceuticals Inc	C	C	B	$794.19
TAKTakeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)	C	C	B	$18.03
TEVATeva Pharmaceutical Industries Limited American Depositary Shares	C	C	C	$36.44
ONCBeOne Medicines Ltd. American Depositary Shares	D	B	B	$366.73
RPRXRoyalty Pharma plc Class A Ordinary Shares	D	D	B	$60.85
ZTSZOETIS INC.	C	C	D	$77.34
ALNYAlnylam Pharmaceuticals, Inc.	D	A	D	$237.10
INSMInsmed, Inc.	F	A	C	$118.54
ROIVRoivant Sciences Ltd. Common Shares	D	F	B	$34.71
UTHRUnited Therapeutics Corp	C	C	B	$515.46
GMABGenmab A/S ADS	C	C	B	$33.23
VTRSViatris Inc. Common Stock	B	C	B	$16.34
ASNDAscendis Pharma A/S Ordinary Share	D	A	C	$247.91
JAZZJazz Pharmaceuticals, Inc.	B	C	B	$244.54
BBIOBridgeBio Pharma, Inc. Common Stock	F	A	B	$76.60
BMRNBioMarin Pharmaceuticals Inc	C	C	B	$64.67
MDGLMadrigal Pharmaceuticals, Inc. Common Stock	D	A	B	$533.76
CORTCorcept Therapeutics Inc.	F	C	B	$113.88
ELANElanco Animal Health Incorporated Common Stock	C	B	C	$24.11
ARWRArrowhead Research Corporation	D	A	B	$84.91
SMMTSummit Therapeutics Inc. Common Stock	F	—	D	$13.73
AXSMAxsome Therapeutics, Inc	D	B	C	$199.02
RDYDr. Reddy's Laboratories Limited American Depositary Shares	D	D	C	$12.18
IONSIonis Pharmaceuticals, Inc. Common Stock	D	D	C	$61.05
CYTKCytokinetics Inc.	F	D	C	$72.09
ABVXAbivax SA American Depositary Shares	—	—	C	$113.35
NUVLNuvalent, Inc. Class A Common Stock	—	—	B	$123.96
PRAXPraxis Precision Medicines, Inc. Common Stock	F	—	B	$344.75
PTGXProtagonist Therapeutics, Inc	F	B	B	$144.33
CRNXCrinetics Pharmaceuticals, Inc.	F	A	A	$84.84
TGTXTG Therapeutics, Inc.	D	B	B	$53.93
SYRESpyre Therapeutics, Inc. Common Stock	—	—	B	$90.36
ALKSAlkermes Inc. plc	D	C	B	$47.41
RYTMRhythm Pharmaceuticals, Inc. Common Stock	F	B	C	$107.17
ERASErasca, Inc. Common Stock	—	—	A	$18.03
TVTXTravere Therapeutics, Inc. Common Stock	F	B	A	$65.67
BLTEBelite Bio, Inc American Depositary Shares	—	—	C	$151.72

About HUTCHMED (China) Limited American Depositary Shares

HUTCHMED is a biopharmaceutical company developing targeted therapies and immunotherapies for cancer and immunological diseases. The company maintains a robust pipeline of cancer drug candidates in clinical development while leveraging significant commercial infrastructure in China. Operating across Oncology/Immunology and Other Ventures segments, HUTCHMED combines early-stage innovation with established regional market presence.